Which has better earnings & valuation, IMMP or SION?

Prima BioMed has higher revenue and earnings than Sionna Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.37 -$39.78M N/A N/A Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A

Is IMMP or SION more profitable?

Prima BioMed's return on equity of 0.00% beat Sionna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Sionna Therapeutics N/A -32.94% -31.08%

Does the media refer more to IMMP or SION?

In the previous week, Sionna Therapeutics had 46 more articles in the media than Prima BioMed. MarketBeat recorded 49 mentions for Sionna Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Sionna Therapeutics' score of -0.30 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 0 Very Positive mention(s) 11 Positive mention(s) 13 Neutral mention(s) 13 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has better valuation and earnings, CGEN or IMMP?

Compugen has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $72.76M 3.13 $35.34M $0.38 6.34 Prima BioMed $6.69M 8.37 -$39.78M N/A N/A

Does the media prefer CGEN or IMMP?

In the previous week, Compugen had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Compugen and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Compugen's score of 1.11 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TARA or IMMP?

Prima BioMed has higher revenue and earnings than Protara Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Prima BioMed $6.69M 8.37 -$39.78M N/A N/A

Is TARA or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Protara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -41.72% -38.78% Prima BioMed N/A N/A N/A

Does the media refer more to TARA or IMMP?

In the previous week, Protara Therapeutics had 12 more articles in the media than Prima BioMed. MarketBeat recorded 15 mentions for Protara Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Protara Therapeutics' score of 0.44 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CAPR or IMMP?

Prima BioMed has lower revenue, but higher earnings than Capricor Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics $22.27M 17.29 -$105.04M -$2.32 N/A Prima BioMed $6.69M 8.37 -$39.78M N/A N/A

Is CAPR or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -58.09% -48.01% Prima BioMed N/A N/A N/A

Does the media refer more to CAPR or IMMP?

In the previous week, Capricor Therapeutics had 57 more articles in the media than Prima BioMed. MarketBeat recorded 60 mentions for Capricor Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Capricor Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 3 Very Positive mention(s) 8 Positive mention(s) 43 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IMMP or CAMP?

Prima BioMed has higher revenue and earnings than CAMP4 Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.37 -$39.78M N/A N/A CAMP4 Therapeutics $3.50M 97.53 -$80.40M -$2.36 N/A

Does the media prefer IMMP or CAMP?

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for CAMP4 Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat CAMP4 Therapeutics' score of -0.16 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CAMP4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Prima BioMed (IMMP) Competitors

$0.38 -0.02 (-5.82%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.26%)

As of 07:22 PM Eastern

Compare

IMMP vs. SION, CGEN, TARA, CAPR, and CAMP

Should you buy Prima BioMed stock or one of its competitors? Prima BioMed's main competitors and comparable companies include Sionna Therapeutics (SION), Compugen (CGEN), Protara Therapeutics (TARA), Capricor Therapeutics (CAPR), and CAMP4 Therapeutics (CAMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prima BioMed compare to Sionna Therapeutics?

Prima BioMed (NASDAQ:IMMP) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Prima BioMed's return on equity of 0.00% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Sionna Therapeutics	N/A	-32.94%	-31.08%

In the previous week, Sionna Therapeutics had 46 more articles in the media than Prima BioMed. MarketBeat recorded 49 mentions for Sionna Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Sionna Therapeutics' score of -0.30 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	0 Very Positive mention(s)	11 Positive mention(s)	13 Neutral mention(s)	13 Negative mention(s)	2 Very Negative mention(s)	Neutral

Prima BioMed has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Sionna Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. Sionna Therapeutics has a consensus target price of $42.22, suggesting a potential upside of 553.59%. Given Prima BioMed's higher probable upside, research analysts clearly believe Prima BioMed is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Prima BioMed shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Prima BioMed beats Sionna Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Prima BioMed compare to Compugen?

Compugen (NASDAQ:CGEN) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, Compugen had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Compugen and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Compugen's score of 1.11 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 107.47%. Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's higher possible upside, analysts plainly believe Prima BioMed is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Compugen has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.13	$35.34M	$0.38	6.34
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A

Compugen has a beta of 2.77, indicating that its stock price is 177% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market.

12.2% of Compugen shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Compugen has a net margin of 47.56% compared to Prima BioMed's net margin of 0.00%. Compugen's return on equity of 42.57% beat Prima BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Prima BioMed	N/A	N/A	N/A

Summary

Compugen beats Prima BioMed on 12 of the 15 factors compared between the two stocks.

How does Prima BioMed compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, Protara Therapeutics had 12 more articles in the media than Prima BioMed. MarketBeat recorded 15 mentions for Protara Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Protara Therapeutics' score of 0.44 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protara Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protara Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Protara Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Protara Therapeutics presently has a consensus target price of $26.25, suggesting a potential upside of 561.21%. Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prima BioMed's return on equity of 0.00% beat Protara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-41.72%	-38.78%
Prima BioMed	N/A	N/A	N/A

Summary

Prima BioMed beats Protara Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Prima BioMed compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Prima BioMed has lower revenue, but higher earnings than Capricor Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	17.29	-$105.04M	-$2.32	N/A
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Capricor Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Prima BioMed's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-58.09%	-48.01%
Prima BioMed	N/A	N/A	N/A

In the previous week, Capricor Therapeutics had 57 more articles in the media than Prima BioMed. MarketBeat recorded 60 mentions for Capricor Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat Capricor Therapeutics' score of 0.00 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	3 Very Positive mention(s)	8 Positive mention(s)	43 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics currently has a consensus price target of $29.15, suggesting a potential upside of 338.35%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,347.37%. Given Prima BioMed's higher possible upside, analysts plainly believe Prima BioMed is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	9 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Prima BioMed beats Capricor Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Prima BioMed compare to CAMP4 Therapeutics?

Prima BioMed (NASDAQ:IMMP) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, CAMP4 Therapeutics had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for CAMP4 Therapeutics and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.21 beat CAMP4 Therapeutics' score of -0.16 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CAMP4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Prima BioMed's return on equity of 0.00% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
CAMP4 Therapeutics	-2,543.74%	-188.63%	-83.62%

2.3% of Prima BioMed shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,347.37%. CAMP4 Therapeutics has a consensus target price of $9.56, suggesting a potential upside of 75.78%. Given Prima BioMed's higher probable upside, equities analysts plainly believe Prima BioMed is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CAMP4 Therapeutics	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Prima BioMed has higher revenue and earnings than CAMP4 Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.37	-$39.78M	N/A	N/A
CAMP4 Therapeutics	$3.50M	97.53	-$80.40M	-$2.36	N/A

Prima BioMed has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

Summary

Prima BioMed beats CAMP4 Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.47M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	N/A	6.29	211.09	21.74
Price / Sales	8.37	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.60	16.78	12.91	6.24
Net Income	-$39.78M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-1.50%	1.74%	1.12%	1.07%
1 Month Performance	-12.20%	1.60%	1.79%	1.03%
1 Year Performance	-77.91%	56.43%	67.69%	20.77%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	3.0172 of 5 stars	$0.38 -5.8%	$5.50 +1,347.4%	-76.7%	$59.47M	$6.69M	N/A	2,021	News Coverage Positive News Short Interest Decrease
SION Sionna Therapeutics	3.0159 of 5 stars	$5.08 +12.8%	$42.22 +731.5%	-68.7%	$225.06M	N/A	N/A	35	Gap Down
CGEN Compugen	4.2655 of 5 stars	$2.38 +1.6%	$5.00 +110.3%	+62.8%	$223.61M	$72.76M	6.22	70	Positive News
TARA Protara Therapeutics	2.6331 of 5 stars	$3.95 -3.9%	$26.25 +564.6%	+20.9%	$220.02M	N/A	N/A	30	News Coverage Earnings Report Analyst Revision Gap Down
CAPR Capricor Therapeutics	2.9019 of 5 stars	$3.79 -1.6%	$29.15 +669.1%	-49.3%	$219.72M	N/A	N/A	101	Trending News Earnings Report Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. SION, CGEN, TARA, CAPR, and CAMP

How does Prima BioMed compare to Sionna Therapeutics?

Summary

How does Prima BioMed compare to Compugen?

Summary

How does Prima BioMed compare to Protara Therapeutics?

Summary

How does Prima BioMed compare to Capricor Therapeutics?

Summary

How does Prima BioMed compare to CAMP4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. SION, CGEN, TARA, CAPR, and CAMP

How does Prima BioMed compare to Sionna Therapeutics?

Is IMMP or SION more profitable?

Does the media refer more to IMMP or SION?

Which has more risk and volatility, IMMP or SION?

Which has better earnings & valuation, IMMP or SION?

Do analysts recommend IMMP or SION?

Do insiders & institutionals hold more shares of IMMP or SION?

Summary

How does Prima BioMed compare to Compugen?

Does the media prefer CGEN or IMMP?

Do analysts rate CGEN or IMMP?

Which has better valuation and earnings, CGEN or IMMP?

Which has more volatility and risk, CGEN or IMMP?

Do institutionals & insiders have more ownership in CGEN or IMMP?

Is CGEN or IMMP more profitable?

Summary

How does Prima BioMed compare to Protara Therapeutics?

Does the media refer more to TARA or IMMP?

Which has more risk and volatility, TARA or IMMP?

Which has better earnings and valuation, TARA or IMMP?

Do insiders and institutionals hold more shares of TARA or IMMP?

Do analysts rate TARA or IMMP?

Is TARA or IMMP more profitable?

Summary

How does Prima BioMed compare to Capricor Therapeutics?

Which has higher valuation and earnings, CAPR or IMMP?

Do insiders & institutionals hold more shares of CAPR or IMMP?

Which has more volatility and risk, CAPR or IMMP?

Is CAPR or IMMP more profitable?

Does the media refer more to CAPR or IMMP?

Do analysts recommend CAPR or IMMP?

Summary

How does Prima BioMed compare to CAMP4 Therapeutics?

Does the media prefer IMMP or CAMP?

Is IMMP or CAMP more profitable?

Do institutionals & insiders have more ownership in IMMP or CAMP?

Do analysts prefer IMMP or CAMP?

Which has higher earnings and valuation, IMMP or CAMP?

Which has more risk & volatility, IMMP or CAMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools